Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies.
about
Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combinationLong-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study.Efficacy and safety of switching to latanoprost 0.005%-timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 monthsSafety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapyEffect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure.Accounting for costs, QALYs, and capacity constraints: using discrete-event simulation to evaluate alternative service delivery and organizational scenarios for hospital-based glaucoma services.Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination.Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapyThe side effects of the prostaglandin analogues.Comparison of latanoprost/timolol with carbonic anhydrase inhibitor and dorzolamide/timolol with prostaglandin analog in the treatment of glaucoma.Latanoprost/timolol fixed combination for the treatment of glaucoma.Efficacy and Safety of Switching from Prostaglandin Analog Therapy to Prostaglandin / Timolol Fixed Combination or Prostaglandin / Brimonidine Therapy.Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients.Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study.
P2860
Q33546682-94D60957-A08F-45BB-A980-650734DECE3AQ33687798-81840B22-3693-4BD7-A1B9-E4FC90EC2C38Q33863765-12C6F1CB-3754-41B5-BB7E-7F1B3B213843Q33867915-A6CA885E-4A47-4C75-9D76-EB3E9BDC2F94Q34182293-37B6D112-5C60-4884-9744-A3E73FA0B067Q34628837-C8B9D7B4-0507-442D-98A1-59BAEAD047AEQ35922145-646ACD03-A4D0-4EC3-9FF2-8B910D545B7AQ36008928-2FE07F82-3C78-416D-AAE3-09CFA091676AQ36689066-51FACABE-A4CE-4647-9D44-8F36242BDBB5Q37661382-9C836E70-9751-4CDA-A98D-6111D5102431Q38117401-017DEE59-548A-4250-A7EE-81F5805C09A2Q41015524-E4421E51-83A7-40F6-A287-D40F8587BDD2Q42551752-1259F973-18A3-4C9C-8B16-E15F14C17C9BQ45929500-90FB6D09-39E3-42BA-A909-F0D8BA2B0189
P2860
Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Short term efficacy and safety ...... pies and adjunctive therapies.
@ast
Short term efficacy and safety ...... pies and adjunctive therapies.
@en
type
label
Short term efficacy and safety ...... pies and adjunctive therapies.
@ast
Short term efficacy and safety ...... pies and adjunctive therapies.
@en
prefLabel
Short term efficacy and safety ...... pies and adjunctive therapies.
@ast
Short term efficacy and safety ...... pies and adjunctive therapies.
@en
P2093
P2860
P356
P1476
Short term efficacy and safety ...... pies and adjunctive therapies.
@en
P2093
A Schölzel-Klatt
E Beausencourt
G Schlaffer
M Schinzel
T Hamacher
P2860
P304
P356
10.1136/BJO.2004.043232
P407
P577
2004-10-01T00:00:00Z